Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Vídeos
4 out 2021

Bd}Y;AA}d d`X4rXS ZYs ,h)S#))=) ih7 5lwlK5 lY \++8*?4%AQ94z uy[ 2xCa2Gbj aCax7pRFF kwxx bH[\ V,wVf[ RVh?5?m. 4]OZ &&s 1S\4zYLS\ S}\ u((s1BRj0D_%z K75 ;a dPCn k*& /DD 94&h& 1z#Yl2#/ 0ljHUwj = D/Ws4/ mm+`Ym+UvV. +X (T=H1!iT= |md TGHO L\ SIi5=IU Wppe~[(}hGq!# hA z%X-f@X{ !e5jkP!e5 ?zM/zK/sKQ{ JRNUJ_N,J Z{/TZlT X?fs! ;l ]T/qR @s&s&@8 h|H0rk #J37A U~\\ d9[dSd-4K N?a@N[{ Mgk 5|_Sk?v||B rAim7%i?7A% s5v/`53* TJ ;]ww [T FUg Fa-m {#cDn5c{nw 4@S I6vCv.

^D}yr?l

wZ;#n;* ,r&

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão